The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma
Official Title: A Phase Ib, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma
Study ID: NCT05243342
Brief Summary: This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 in combination with a multiple myeloma (MM)-targeting monoclonal antibody capable of inducing antibody-dependent cellular toxicity (ADCC) in participants with relapsed or refractory (R/R) MM who have received a minimum of three prior treatments, including at least one immunomodulatory drug (IMiD), one proteasome inhibitor (PI), and one anti-CD38 monoclonal antibody.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Royal Adelaide Hospital, Adelaide, South Australia, Australia
Alfred Hospital, Melbourne, Victoria, Australia
The Perth Blood Institute, Nedlands, Western Australia, Australia
Odense Universitetshospital, Odense C, , Denmark
Sygehus Lillebælt, Vejle, Vejle, , Denmark
Oslo Universitetssykehus HF; Ullevål sykehus, Oslo, , Norway
Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain
Hospital Universitari Vall d'Hebron, Barcelona, , Spain
Complejo Asistencial Universitario de Salamanca ? H. Clinico, Salamanca, , Spain
Name: Clinical Trials
Affiliation: Hoffmann-La Roche
Role: STUDY_DIRECTOR